Author

L. Jin

Observed name: Li-xia Jin

Institution: Bristol-Myers Squibb (United States)

Observed institutions: Zhejiang Chinese Medical University, Bristol-Myers Squibb (United States), Novartis (United States)

ORCID: 0009-0004-4877-3587

Observed ORCID: 0009-0004-4877-3587

OpenAlex ID: A5108990004

The Effect of Zoledronic Acid on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: The Z-FAST Study 5-Year Final Follow-Up.

2009 · A. Brufsky, G. Harker, et al. · Cancer Research · 59

Pan-Cancer Screening and Validation of CALU’s Role in EMT Regulation and Tumor Microenvironment in Triple-Negative Breast Cancer

2024 · Shi-liang Chen, Dan Hu, et al. · Journal of Inflammation Research · 14

Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): first results of the CheckMate 8HW study

2024 · G. Folprecht, T. Andre, et al. · Zeitschrift für Gastroenterologie · 13

1209P A phase II study of regorafenib in combination with nivolumab in patients with recurrent or metastatic solid tumors: Results of the ESCC cohort

2022 · L-Y. Bai, C-F. Chiu, et al. · Annals of Oncology · 6

LBA29 Nivolumab plus ipilimumab vs nivolumab monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): New results from CheckMate 8HW

2025 · S. Lonardi, H.J. Lenz, et al. · Annals of Oncology · 4

541P Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Subgroup efficacy and expanded safety analyses from CheckMate 8HW

2024 · T. André, S. Lonardi, et al. · Annals of Oncology · 4

2O Health-related quality of life (HRQoL) with first-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW

2024 · S. Lonardi, T. André, et al. · Annals of Oncology · 4

1027TiP A phase Ib study of CM24 in combination with nivolumab in adults with advanced solid tumors, followed by a phase IIa study of CM24 in combination with nivolumab in NSCLC, and in combination with nivolumab and nab-paclitaxel in pancreatic cancer

2021 · E. Borazanci, M.N. Al Hallak, et al. · Annals of Oncology · 2

Nivolumab plus ipilimumab and cobimetinib in previously treated microsatellite-stable/DNA mismatch repair-proficient metastatic colorectal cancer: the phase II CheckMate 142 trial

2026 · M.J. Overman, S. McCraith, et al. · ESMO Gastrointestinal Oncology · 1

1O Nivolumab (NIVO) plus ipilimumab (IPI) vs NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Health-related quality of life (HRQoL) analyses from CheckMate 8HW

2025 · E. Elez Fernandez, T. André, et al. · Annals of Oncology · 1

163TiP Phase II/III trial of first-line pumitamig (PD-L1 × VEGF-A bsAb) + chemotherapy vs bevacizumab + chemotherapy in unresectable/metastatic colorectal cancer (ROSETTA CRC-203)

2026 · S. Lonardi, T. Biachi de Castria, et al. · Annals of Oncology

Clinical factors for predicting clinical responses to methotrexate

2019 · K.X. Yan, Y.J. Zhang, et al. · British Journal of Dermatology

Works count: 12

Citation count: 106

H-index: 4

I10-index: 3